Orchid Pharma profit falls 57% on higher costs; auditor flags US units
Standalone net profit for FY26 dropped to ₹45.2 crore from ₹106.5 crore, confirming a severe earnings slide first signaled in Q3.
— 5 earlier stories on Orchid Pharma Ltd. →What's new
- FY26 standalone net profit fell 57% to ₹45.2 cr from ₹106.5 cr the prior year.
- Consolidated net profit plunged 79% to ₹20.5 cr, with auditors issuing a qualified opinion.
- Q4 standalone profit rose to ₹30.6 cr, a sequential recovery but still modest.
Why this matters
The earnings collapse is now audited and confirmed. The qualified opinion on consolidated accounts over three unaudited US subsidiaries adds a governance headache on top of the margin compression. This was largely anticipated after Q3 and a credit rating downgrade, but the final numbers remove any ambiguity about the scale of the deterioration.
What we're watching
- Management's explanation for the 79% consolidated profit drop beyond 'higher costs'.
- Any corrective action or audits planned for the US subsidiaries flagged by the auditor.
- Whether the Q4 standalone sequential recovery can be sustained into FY27.
The full read
Orchid Pharma's audited FY26 results are in, and they're bad. Standalone net profit fell 57% to ₹45.2 crore from ₹106.5 crore the prior year. The consolidated picture is worse: a 79% collapse to ₹20.5 crore. The fourth quarter did show a sequential bounce to ₹30.6 crore in standalone profit, but that single quarter accounts for over two-thirds of the year's total earnings. The consolidated accounts come with a qualified auditor opinion, a red flag over three unaudited US subsidiaries the auditor says have negligible operations. These results were widely anticipated after Q3 showed the same slide and a credit downgrade followed. This filing removes any doubt about the scale of the damage. The open question is whether the Q4 uptick is a bottom or just the low base of a terrible year.
Questions answered
- Why did consolidated profit fall much harder than standalone?
- Consolidated net profit fell 79% to ₹20.5 crore, compared to a 57% drop in standalone. The filing attributes this to margin compression and higher costs, but the precise drivers of the wider consolidated decline aren't detailed.
- What did the auditor's qualified opinion involve?
- The statutory auditor gave an unmodified opinion on the standalone books but a qualified opinion on the consolidated accounts. The qualification concerns the unaudited financials of three US subsidiaries with negligible operations.
- How does Q4 standalone profit compare to the full year?
- Q4 standalone profit was ₹30.6 crore, which is more than two-thirds of the entire FY26 standalone profit of ₹45.2 crore. This points to a severe earnings collapse in the first three quarters.
- Were these results anticipated?
- Yes. The rationale notes the results confirm earnings deterioration already flagged in Q3 results and a credit rating downgrade. This filing is an audited confirmation, not a new warning.
Story so far
All notes on ORCHPHARMA →- 25 May 2026 · 8:00 PM IST Orchid Pharma profit falls 57% on higher costs; auditor flags US units
- today NCLT clears Orchid-Dhanuka merger. Integration starts now.
- 4d ago Orchid expects Enmetazobactam deal this quarter, eyes US sterile market
- 10d ago Orchid Pharma lifts Enmetazobactam lifetime sales target to $2 billion
- 11d ago Orchid Pharma annual profit drops to ₹45.2 crore